Biogen Inc., of Cambridge, Mass., reported that its total revenues in the third quarter 2017 were $3.1 billion, a 4 percent increase vs. the prior year or a 13 percent increase excluding hemophilia revenues from Q3 2016 (in Q1 2017 the company completed the separation of its global hemophilia business into Bioverativ Inc., a public company).